2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: Effect of technetium chelate on tumor uptake and pharmacokinetics

Bioconjugate Chemistry

Volumn 20, Issue 8, 2009, Pages 1559-1568

  Shi, Jiyun ^a   Kim, Young Seung ^a   Chakraborty, Sudipta ^a   Jia, Bing ^b   Wang, Fan ^b   Liu, Shuang ^a  

^a PURDUE UNIVERSITY   (United States)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATION; MAMMALS; RADIOACTIVE TRACERS; TECHNETIUM; TECHNETIUM COMPOUNDS;

ATHYMIC; BI-FUNCTIONAL; BIFUNCTIONAL CHELATING AGENT; HIGHER YIELD; LABELINGS; NUDE MICE; POST INJECTION; TECHNETIUM-; TUMOR IMAGING; TUMOR UPTAKE;

TUMORS;

CHELATING AGENT; DECANOIC ACID; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; S BENZOYLMERCAPTOACETYLGLYCYLGLYCYL 15 AMINO 4,7,10,13 TETRAOXAPENTADECANOIC ACID ARGINYLGLYCYLASPARTIC ACID 2 TC 99M; S BENZOYLMERCAPTOACETYLGLYCYLGLYCYL 3 15 AMINO 4,7,10,13 TETRAOXAPENTADECANOIC ACID ARGINYLGLYCYLASPARTIC ACID 2 TC 99M; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; CYCLIC ARGININE GLYCINE ASPARTIC ACID PEPTIDE; CYCLIC ARGININE-GLYCINE-ASPARTIC ACID PEPTIDE; CYCLOPEPTIDE; DIPEPTIDE; S BENZOYLMERCAPTOACETYLGLYCYLGLYCYL; S-BENZOYLMERCAPTOACETYLGLYCYLGLYCYL; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BRAIN; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG UPTAKE; EYE; GLIOMA; HEART; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; INTESTINE; KIDNEY; LIPOPHILICITY; LIVER; LUNG; MOUSE; MUSCLE; NONHUMAN; NUDE MOUSE; SPLEEN; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CHEMICAL STRUCTURE; CHEMISTRY; DIMERIZATION; EXPERIMENTAL NEOPLASM; ISOTOPE LABELING; METABOLISM; STEREOISOMERISM;

MUS MUSCULUS;

ANIMALS; CHELATING AGENTS; DIMERIZATION; DIPEPTIDES; GLIOMA; HUMANS; ISOTOPE LABELING; MICE; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PEPTIDES, CYCLIC; STEREOISOMERISM; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 70349156433     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc9001739     Document Type: Article

References (60)

1. Weber, W. A., Haubner, R., Vabuliene, E., Kuhnast, B., Webster, H. J., and Schwaiger, M. (2001) Tumor angiogenesis targeting using imaging agents. Q. J. Nucl. Med. 45, 179-182. (Pubitemid 32640393)
2. Liu, S., and Edwards, D. S. (2002) Fundamentals of receptor-based diagnostic metalloradiopharmaceuticals. Top. Curr. Chem. 222, 259-278.
3. Van de Wiele, C., Oltenfreiter, R., De Winter, O., Signore, A., Slegers, G., and Dieckx, R. A. (2002) Tumor angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging. Eur. J. Nucl. Med. 29, 699-709. (Pubitemid 34439332)
4. 3 directed radiopharmaceuticals for tumor imaging. Drugs Future 28, 551-564.
5. Haubner, R., and Wester, H. J. (2004) Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of antiantiogenic therapies. Curr. Pharmaceut. Des. 10, 1439-1455. (Pubitemid 38559759)
6. D'Andrea, L. D., Del Gatto, A., Pedone, C., and Benedetti, E. (2006) Peptide-based molecules in angiogenesis. Chem. Biol. Drug Des. 67, 115-126.
7. Meyer, A., Auremheimer, J., Modlinger, A., and Kessler, H. (2006) Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharmaceut. Des. 12, 2723-2747. (Pubitemid 44184633)
8. 3 expression. Mini-Rev. Med. Chem. 6, 227-234.
9. 3-targeted radiotracers for tumor imaging. Mol. Pharm. 3, 472-487.
10. Cai, W., and Chen, X. (2008) Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 49, 113S-128S. (Pubitemid 351948040)
11. Cai, W., Niu, G., and Chen, X. (2008) Imaging of integrins as biomarkers for tumor angiogenesis. Curr. Pharmaceut. Des. 14, 2943-2973. (Pubitemid 351948040)
12. Hsu, A., and Chen, X. (2008) Aances in anatomic, functional, and molecular imaging of angiogenesis. J. Nucl. Med. 49, 511-514.
13. Van Hagen, P. M., Breeman, W. A. P., Bernard, H. F., Schaar, M., Mooij, C. M., Srinivasan, A., Schmidt, M. A., Krenning, E. P., and de Jong, M. (2000) Evaluation of a radiolabeled cyclic DTPA-RGD analog for tumor imaging and radionuclide therapy. Int. J. Cancer (Radiat. Oncol. Invest.) 90, 186-198.
14. Huabner, R., Wester, H. J., Senekowitsch-Schmidtke, R., Diefenbach, B., Kessler, H., Stöcklin, G., and Schwaiger, M. (1997) RGD-peptides for tumor targeting: biological evaluation of radioiodinated analogs and introduction of a novel glycosylated peptide with improved biokinetics. J. Labelled Compd. Radiopharm. 40, 383-385.
15. 99m labeled RGD-containing synthetic peptide. Eur. J. Nucl. Med. 25, 1383-1389.
16. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61, 1781-1785.
17. 3 integrin antagonists: a new class of tracers for tumor imaging. J. Nucl. Med. 40, 1061-1071.
18. Haubner, R., Wester, H. J., Burkhart, F., Senekowisch- Schmidtke, R., Weber, W., Goodman, S. L., Kessler, H., and Schwaiger, M. (2001) Glycolated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42, 326-336. (Pubitemid 32150525)
19. 3 expression. Nuklearmedizin 43, 26-32.
20. Thumshirn, G., Hersel, U., Goodman, S. L., and Kessler, H. (2003) Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chem. Eur. J. 9, 2717-2725.
21. Poethko, T., Schottelius, M., Thumshirn, G., Herz, M., Haubner, R., Henriksen, G., Kessler, H., Schwaiger, M., and Wester, H. J. (2004) Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochim. Acta 92, 317-327.
22. 18F-labeled RGD and octreotide analogs. J. Nucl. Med. 45, 892-902.
23. 3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-D-Tyr-Lys). Bioconjugate Chem. 18, 530-537.
24. 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis. Anticancer Res. 26, 431-434.
25. 3 integrin for tumor imaging. Bioconjugate Chem. 13, 561-570.
26. 3 expression. Nucl. Med. Biol. 33, 945-952.
27. 64Cu-labeled RGD peptide. Bioconjugate Chem. 15, 41-49.
28. Chen, X., Park, R., Shahinian, A. H., Tohme, M., Khankaldyyan, V., Bozorgzadeh, M. H., Bading, J. R., Moats, R., Laug, W. E., and Conti, P. S. (2004) 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl. Med. Biol. 31, 179-189. (Pubitemid 38315112)
29. Chen, X., Park, R., Shahinian, A. H., Bading, J. R., and Conti, P. S. (2004) Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl. Med. Biol. 31, 11-19. (Pubitemid 38115121)
30. 64Cu-labeled dimeric RGD peptides. Mol. Imaging Biol. 6, 350-359.
31. 18F-labeled dimeric RGD peptide. Mol. Imaging 3, 96-104.
32. 64Cu-labeled tetrameric RGD peptide. J. Nucl. Med. 46, 1707-1718.
33. 18F-FRGD2. J. Nucl. Med. 47, 113-121.
34. 18F-FPRGD4). J. Nucl. Med. 48, 1536-1544.
35. 3 integrin receptor-targeted imaging agent. Appl. Radiat. Isot. 65, 70-78.
36. 3 expression. Eur. J. Nucl. Med. Mol. Imaging 35, 1100-1108.
37. 177Lu-labeling of a DOTA-conjugated vitronectin receptor antagonist for tumor therapy. Bioconjugate Chem. 12, 559-568.
38. Janssen, M., Oyen, W. J. G., Massuger, L. F. A. G., Frielink, C., Dijkgraaf, I., Edwards, D. S., Rajopadyhe, M., Corsten, F. H. M., and Boerman, O. C. (2002) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother. Radiopharm. 17, 641-646. (Pubitemid 36025945)
39. 3 binding peptides in a nude mice model. Cancer Res. 62, 6146-6151.
40. Janssen, M. L., Frielink, C., Dijkgraaf, I., Oyen, W. J., Edwards, D. S., Liu, S., Rajopadhye, M., Massuger, L. F., Corstens, F. H. M., and Boerman, O. C. (2004) Improved tumor targeting of radiolabeled RGD-peptides using rapid dose fractionation. Cancer Biother. Radiopharm. 19, 399-404. (Pubitemid 39281331)
41. 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. Bioconjugate Chem. 16, 1580-1588.
42. 3 expression. Bioconjugate Chem. 17, 1069-1076.
43. 99mTc- labeled cyclic RGDfK dimer. Bioconjugate Chem. 17, 1499-1507.
44. 3-positive breast cancer. Bioconjugate Chem. 18, 438-446.
45. Dijkgraaf, I., Liu, S., Kruijtzer, J. A. W., Soede, A. C., Oyen, W. J. G., Liskamp, R. M. J., Corstens, F. H. M., and Boerman, O. C. (2007) Effects of linker variation on the in vitro and in vivo characteristics of an 111 In-labeled RGD peptide. Nucl. Med. Biol. 34, 29-35. (Pubitemid 46038156)
46. 3 integrin by multimerization of RGD peptides. Eur. J. Nucl. Med. Mol. Imaging 34, 267-273.
47. 99mTc-labeled cyclic RGDfK tetramer. Nucl. Med. Biol. 35, 111-121.
48. Jia, B., Liu, Z., Shi, J., Yu, Z. L., Yang, Z., Zhao, H. Y., He, Z. J., Liu, S., and Wang, F. (2008) Linker effects on biological properties of 111 In-labeled DTPA conjugates of a cyclic RGDfK dimer. Bioconjugate Chem. 19, 201-210. (Pubitemid 351213852)
49. 99mTc-labeling of HYNIC-conjugated cyclic RGDfK dimer and tetramer using EDDA as coligand. Bioconjugate Chem. 19, 634-642.
50. 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J. Nucl. Med. 50, 116-122.
51. 18F-AH111585 in breast cancer patients. J. Nucl. Med. 49, 879-886.
52. 18F-Galacto-RGD in cancer patients. J. Nucl. Med. 46, 1333-1341.
53. 18F]Galacto-RGD. PLOS Med. 2: e70, 244-252.
54. 3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13, 6610-6616.
55. 4 linkers. Mol. Pharm. 6, 231-245.
56. 99mTc-labeled cyclic Arginine-Glycine-Aspartic (RGD) dimers with triglycine linkers. J. Med. Chem. 51, 7980-7990.
57. 4 Linkers. Bioconjugate Chem. Accepted.
58. 99mTc-chelator-peptide conjugates. Bioconjugate Chem. 7, 196-202.
59. Cai, W., Rao, J., Gambhir, S. S., and Chen, X. (2006) How molecular imaging is speeding up antiangiogenic drug development? Mol. Cancer Ther. 5, 2624-2633. (Pubitemid 44848989)
60. Niu, G., and Chen, X. (2008) Has molecular and cellular imaging enhanced drug discovery and drug development? Drugs R&D 9, 351-368.